Research Paper Volume 15, Issue 16 pp 8471—8486
Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer
Figure 5. The ES predicting the sensitivity to chemosensitivity and endocrine therapy. (C) docetaxel, (D) doxorubicin, (E) cisplatin, (F) tamoxifen, and (G) fulvestrant; (H) Raincloud Plot showing the comparison of ES between endocrine therapy non-responder and responder groups. ES, exosome score; IC50, half maximal inhibitory concentration.